Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antidepressant effects of psilocybin without serotonergic psychedelic experience
2025-521690-14-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin and pimavanserin in major depressive disorder (MDD) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Resting-state functional MRI connectivity (beta measures). Planned start May 2026; status: authorised.
02
Drugs
psilocybinpimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-521690-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521690-14-00.